Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drug regimen shows promise for rare vision disorder

NCT ID NCT05666804

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 03, 2026 · Updated 12 times

Summary

This study tested a personalized treatment plan using the drug brolucizumab for people with a specific eye condition called polypoidal choroidal vasculopathy (PCV), which can cause vision loss. The trial involved 148 adults who had not received prior treatment for this condition. The goal was to see if a tailored dosing schedule could safely control the disease and improve or maintain eyesight over 60 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MACULAR POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Daegu, Dalseo Gu, 42602, South Korea

  • Novartis Investigative Site

    Bundang Gu, Gyeonggi-do, 13620, South Korea

  • Novartis Investigative Site

    Daejeon, Korea, 35015, South Korea

  • Novartis Investigative Site

    Seoul, Korea, 02447, South Korea

  • Novartis Investigative Site

    Seoul, Korea, 03080, South Korea

  • Novartis Investigative Site

    Busan, 48108, South Korea

  • Novartis Investigative Site

    Busan, 49241, South Korea

  • Novartis Investigative Site

    Busan, 613-815, South Korea

  • Novartis Investigative Site

    Daegu, 705703, South Korea

  • Novartis Investigative Site

    Gwangju, 61469, South Korea

  • Novartis Investigative Site

    Seoul, 01000, South Korea

  • Novartis Investigative Site

    Seoul, 01869, South Korea

  • Novartis Investigative Site

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    Seoul, 06273, South Korea

Conditions

Explore the condition pages connected to this study.

MACULAR POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV)